

1 **Supplementary File 1: Additional Background Information**

2

3 **EVIDENCE OF MECHANISM**

4 In recent years, evidence of mechanism between maternal supine sleeping position
5 after 28 weeks gestation, foetal growth restriction, and late stillbirth has been
6 mounting.(1–13) For example, Couper et al., using advanced magnetic resonance
7 imaging techniques, demonstrated that in healthy pregnancies, the maternal supine
8 position results in a 23.7% reduction in total internal iliac artery blood flow, a 6.2%
9 reduction in oxygen delivery to the foetus, and an 11% reduction in foetal umbilical
10 venous blood flow compared to the lateral position.(3) Based on the first of these three
11 findings, a simple calculation can be performed to demonstrate that, from 28 through 40
12 weeks' gestation, if two hours per day were spent supine,(14–22) assuming an average
13 of 500 ml/min of maternal blood going to the uterus and 80% of this going to the
14 placenta,(23) the intervillous space (maternal side) of the placenta would experience a
15 cumulative 1,000 litre deficit.

16 Furthermore, in the supine position, maternal respiratory parameters are affected.
17 Because of increased abdominal pressure when supine, the functional residual capacity
18 of the lungs decreases, the alveolar-arterial oxygen difference increases, and lung
19 compliance decreases.(24–26) Studies have also shown deeper maternal oxygen
20 desaturations, higher apnea-hypopnea index, higher 3% oxygen desaturation index,
21 and higher respiratory disturbance index when sleeping supine in pregnancy.(14,21)
22 Arterial partial pressure of oxygen is lower when supine in pregnancy.(24,27)

23

24 Taken together, it is intuitive that maternal supine sleep could affect foetal growth and,
25 consequently, risk of stillbirth via decreased placental blood and oxygen supply.

26 **GESTATION RELATED OPTIMAL WEIGHT STANDARD**

27 The original Ghana PrenaBelt Trial (GPT)(28) selected the Gestation Related Optimal
28 Weight (GROW) standard by Gardosi et al. (Perinatal Institute and Gestation Network,
29 Birmingham, UK) as one of its primary outcomes.(29,30) The reason for using the
30 GROW standard in the original GPT and in this study is because the GROW standard
31 accounts for the main six non-pathological factors affecting birth weight, including
32 gestational age, maternal height, maternal weight at booking, parity, ethnicity and sex of
33 the neonate. As such, the customised birthweight centile (CBWC) computed using the
34 GROW standard enables delineation between constitutional and pathological smallness
35 and more accurate detection of pregnancies at increased risk for adverse
36 outcomes.(31,32)

37 **Changes in the GROW Standard Calculators Between Original and Current** 38 **Analyses**

39 The GROW standard calculators are continually being updated, according to availability
40 of new databases from different populations from which additional ethnic coefficients
41 can be derived.(33) This enables improvement on predicting normal variation, which
42 reflect on the coefficient of variation of the curve. The extent of the data have enabled
43 derivation of ethnic-specific sets of coefficients.(33) That is, GROW calculators adjust
44 for maternal height and weight, parity, and sex of the neonate for each ethnicity or

45 country of origin.(33) As such, because we used the "Ghanaian" ethnicity coefficient
46 with the new (v.8.0.6.2) calculator, all the other coefficients in the model (maternal
47 height and weight, parity, and sex of the neonate) were changed based on new
48 datasets from Ghana because these coefficients are specific to the "Ghanaian"
49 ethnicity. In the original GPT analysis with the old (v6.7.8.1) calculator, the authors used
50 the "West African" ethnicity coefficient (based on West Africans giving birth at Queen's
51 Medical Centre, Nottingham, UK), which had its own set of coefficients for maternal
52 height and weight, parity, and sex of the neonate.

53 Role of Maternal Ethnicity in Customised Foetal Growth Standards

54 We acknowledge that ethnicity can be poorly defined by both patients and clinicians and
55 that assumptions about the impact of ethnicity on health has the potential to result in
56 patient harm. However, several decades of epidemiological research along with several
57 professional organisations (e.g., the Royal College of Obstetricians &
58 Gynaecologists)(34) have established that the benefit outweighs the harm when
59 assessing birth weight against individual growth potential calculated for each baby in
60 each pregnancy (customised standards) rather than against the average of the
61 population (population standards or norms).(35,36) Customised standards, adjusted for
62 the main factors affecting foetal growth (including ethnicity), increase accurate detection
63 of IUGR by improved distinction between physiological and pathological smallness.(35)
64 In contrast, application of population standards fails to identify a significant proportion of
65 pathological smallness (false negative) and erroneously identifies a significant
66 proportion of physiological smallness as IUGR (false positive, risking unnecessary and

67 potentially harmful intervention).(37–39) In a study of over 130,000 births from 2009-
68 2013, Gardosi et al. have demonstrated that maternal height, maternal weight, maternal
69 ethnicity, parity, and sex of the newborn account for 76% (R-squared 0.759) of the
70 normal variation in birth weight (excluding pathological factors).(36) Regarding the
71 impact of ethnicity alone, it accounts for approximately 24% of the normal variation in
72 birth weight,(36) which highlights the clinical importance of taking maternal ethnicity into
73 account. Finally, there is now a substantial evidence base that supports that differences
74 in foetal growth potential between ethnic groups are physiologic and that customization
75 (which accounts for ethnicity) improves delineation between pathological and
76 physiological smallness.(40–44)

77 **COMPARISON OF FREQUENTIST AND BAYESIAN PARADIGMS**

78 In the frequentist paradigm, the study hypothesis is evaluated indirectly by estimating an
79 objective probability, a relative long-run frequency (also known as the p-value), of
80 observing a treatment effect of the same or larger magnitude than the treatment effect
81 observed in a given study if the same study were repeated indefinitely and assuming
82 the null hypothesis (no effect) is true.(45) According to Royall, the frequentist approach
83 can only guide our decision to either accept or reject the null hypothesis – in light of
84 data, frequentist statistics tells us what to *do*.(46) If we want to know, in light of data,
85 what we should *believe* or how strongly we should believe in different hypotheses,
86 frequentist methods cannot answer that question and, rather, Bayesian methods are
87 required.(46)

88 In the Bayesian paradigm, the study hypothesis is evaluated directly, that is, Bayesian
89 methods tell us the probability of the study hypothesis being true given the available
90 data.(47,48) Bayes' theorem enables the estimation of a plausible range of values of a
91 treatment effect ("posterior probability") by formally combining data collected in a study
92 with information available prior to the study about the plausible values of a treatment
93 effect ("prior probability").(45) In other words, a unique feature of a Bayesian analysis is
94 that it enables the use of clinically relevant priors probabilities in combination with trial
95 data to provide updated and robust estimates that allow for a more comprehensive
96 interpretation of the existing evidence. As such, one can appreciate the utility of
97 Bayesian methods in clinical practice as clinical decisions can be directly informed by
98 study results and, at the same time, incorporate the influence of clinical judgement and
99 prior beliefs about the treatment effect.(47,49,50)

100 For readers who may be sceptical of Bayesian methodology, we direct them to a
101 thorough discussion of the rationale, process, and interpretation of Bayesian analyses in
102 a recent, open-access, systematic review in the *Lancet*, "Clinical trials in critical care:
103 can a Bayesian approach enhance clinical and scientific decision making?" by Yarnell,
104 Abrams, Baldwin, et al.(51)

105 REFERENCES

- 106 1. Jaffa AJ, Gull I, Amster R, Lessing JB, Wolman I. Effect of the supine position on uterine
107 and umbilical blood flow during the third trimester of uncomplicated pregnancies in
108 multiparous patients. *Gynecol Obstet Invest.* 2001;52(4):252–6.
- 109 2. Ryo E, Okai T, Kozuma S, Kobayashi K, Kikuchi A, Taketani Y. Influence of compression of
110 the inferior vena cava in the late second trimester on uterine and umbilical artery blood flow.
111 *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet.* 1996 Dec;55(3):213–8.
- 112 3. Couper S, Clark A, Thompson JMD, Flouri D, Aughwane R, David AL, et al. The effects of
113 maternal position, in late gestation pregnancy, on placental blood flow and oxygenation: an
114 MRI study. *J Physiol.* 2021 Mar;599(6):1901–15.

- 115 4. Karimu AL, Burton GJ. The effects of maternal vascular pressure on the dimensions of the
116 placental capillaries. *Br J Obstet Gynaecol.* 1994 Jan;101(1):57–63.
- 117 5. Kranenburg-Lakeman P, Boer K, van Gemert MJ, Vergroesen I. In vitro placental pressure-
118 flow behaviour is non-linear and depends on the external pressure. *Eur J Obstet Gynecol*
119 *Reprod Biol.* 2001 Nov;99(1):77–84.
- 120 6. Zun Z, Zaharchuk G, Andescavage NN, Donofrio MT, Limperopoulos C. Non-Invasive
121 Placental Perfusion Imaging in Pregnancies Complicated by Fetal Heart Disease Using
122 Velocity-Selective Arterial Spin Labeled MRI. *Sci Rep.* 2017 Nov 23;7(1):16126.
- 123 7. Abaci Turk E, Abulnaga SM, Luo J, Stout JN, Feldman HA, Turk A, et al. Placental MRI:
124 Effect of maternal position and uterine contractions on placental BOLD MRI measurements.
125 *Placenta.* 2020 Jun;95:69–77.
- 126 8. Silva KP, Hamamoto TENK, Nomura RMY. Transient fetal blood redistribution associated
127 with maternal supine position. *J Perinat Med.* 2017 Apr 1;45(3):343–7.
- 128 9. Khatib N, Weiner Z, Beloosesky R, Vitner D, Thaler I. The effect of maternal supine position
129 on umbilical and cerebral blood flow indices. *Eur J Obstet Gynecol Reprod Biol.* 2014
130 Apr;175:112–4.
- 131 10. van Katwijk C, Wladimiroff JW. Effect of maternal posture on the umbilical artery flow
132 velocity waveform. *Ultrasound Med Biol.* 1991;17(7):683–5.
- 133 11. Ryo E, Okai T, Takagi K, Okuno S, Sadatsuki M, Kaneko M, et al. Comparison of umbilical
134 artery Doppler velocimetry between maternal supine position and complete left lateral
135 position in predicting obstetric complications. *Ultrasound Obstet Gynecol.* 1998;11(6):415–
136 8.
- 137 12. Sorensen TK, Hendricks S, Easterling TR, Carlson KL, Benedetti TJ. Effect of orthostatic
138 stress on umbilical Doppler waveforms in normal and hypertensive pregnancies. *Am J*
139 *Obstet Gynecol.* 1992 Sep;167(3):643–7.
- 140 13. Stone PR, Burgess W, McIntyre JPR, Gunn AJ, Lear CA, Bennet L, et al. Effect of maternal
141 position on fetal behavioural state and heart rate variability in healthy late gestation
142 pregnancy. *J Physiol.* 2017 Feb 15;595(4):1213–21.
- 143 14. Wilson DL, Fung AM, Pell G, Skrzypek H, Barnes M, Bourjeily G, et al. Polysomnographic
144 analysis of maternal sleep position and its relationship to pregnancy complications and
145 sleep-disordered breathing. *Sleep.* 2022 Apr 11;45(4):zsac032.
- 146 15. Kember AJ, Scott HM, O'Brien LM, Borazjani A, Butler MB, Wells JH, et al. Modifying
147 maternal sleep position in the third trimester of pregnancy with positional therapy: a
148 randomised pilot trial. *BMJ Open.* 2018 Aug 29;8(8):e020256.
- 149 16. Warland J, Dorrian J, Kember AJ, Phillips C, Borazjani A, Morrison JL, et al. Modifying
150 Maternal Sleep Position in Late Pregnancy Through Positional Therapy: A Feasibility Study.
151 *J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med.* 2018 Aug 15;14(8):1387–97.
- 152 17. McIntyre JPR, Ingham CM, Hutchinson BL, Thompson JMD, McCowan LM, Stone PR, et al.
153 A description of sleep behaviour in healthy late pregnancy, and the accuracy of self-reports.
154 *BMC Pregnancy Childbirth.* 2016 May 18;16(1):115.
- 155 18. Warland J, Dorrian J. Accuracy of Self-Reported Sleep Position in Late Pregnancy. *PLOS*
156 *ONE.* 2014 Dec 23;9(12):e115760.
- 157 19. O'Brien LM, Warland J. Typical sleep positions in pregnant women. *Early Hum Dev.* 2014
158 Jun;90(6):315–7.
- 159 20. Wilson DL, Barnes M, Ellett L, Permezel M, Jackson M, Crowe SF. Decreased sleep
160 efficiency, increased wake after sleep onset and increased cortical arousals in late
161 pregnancy. *Aust N Z J Obstet Gynaecol.* 2011 Feb;51(1):38–46.
- 162 21. Dunietz GL, Sever O, DeRowe A, Tauman R. Sleep position and breathing in late
163 pregnancy and perinatal outcomes. *J Clin Sleep Med.* 2020 Jun 15;16(6):955–9.
- 164 22. Maasilta P, Bachour A, Teramo K, Polo O, Laitinen LA. Sleep-related disordered breathing
165 during pregnancy in obese women. *Chest.* 2001 Nov;120(5):1448–54.

- 166 23. Cunningham F, Leveno K, Bloom S, Spong C, Dashe J, Hoffman B, et al. Maternal
167 Physiology. In: Williams Obstetrics. 24th ed. McGraw-Hill Education; p. 47.
- 168 24. Prodromakis E, Trakada G, Tsapanos V, Spiropoulos K. Arterial oxygen tension during
169 sleep in the third trimester of pregnancy. *Acta Obstet Gynecol Scand*. 2004 Feb;*83*(2):159–
170 64.
- 171 25. Hignett R, Fernando R, McGlennan A, McDonald S, Stewart A, Columb M, et al. A
172 randomized crossover study to determine the effect of a 30° head-up versus a supine
173 position on the functional residual capacity of term parturients. *Anesth Analg*. 2011
174 Nov;*113*(5):1098–102.
- 175 26. Aretha D, Fligou F, Kiekkas P, Messini C, Panteli E, Zintzaras E, et al. Safety and
176 effectiveness of alveolar recruitment maneuvers and positive end-expiratory pressure during
177 general anesthesia for cesarean section: a prospective, randomized trial. *Int J Obstet*
178 *Anesth*. 2017 May;*30*:30–8.
- 179 27. Spiropoulos K, Prodromaki E, Tsapanos V. Effect of body position on PaO₂ and PaCO₂
180 during pregnancy. *Gynecol Obstet Invest*. 2004;*58*(1):22–5.
- 181 28. Coleman J, Okere M, Seffah J, Kember A, O'Brien LM, Borazjani A, et al. The Ghana
182 PrenaBelt trial: a double-blind, sham-controlled, randomised clinical trial to evaluate the
183 effect of maternal positional therapy during third-trimester sleep on birth weight. *BMJ Open*.
184 2019 Apr 1;*9*(4):e022981.
- 185 29. Gardosi J, Francis A. Gestation Network. [cited 2022 Mar 10]. Gestation Network Centile
186 Calculator. Available from: <https://www.gestation.net/cc/about.htm>
- 187 30. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth
188 charts. *The Lancet*. 1992 Feb 1;*339*(8788):283–7.
- 189 31. Gardosi J. New definition of small for gestational age based on fetal growth potential. *Horm*
190 *Res*. 2006;*65* Suppl 3:15–8.
- 191 32. Odibo AO, Francis A, Cahill AG, Macones GA, Crane JP, Gardosi J. Association between
192 pregnancy complications and small-for-gestational-age birth weight defined by customized
193 fetal growth standard versus a population-based standard. *J Matern-Fetal Neonatal Med Off*
194 *J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet*. 2011
195 Mar;*24*(3):411–7.
- 196 33. Gardosi J. GROW 1.5 Documentation December 2020 [Internet]. Gestation Network and
197 Perinatal Institute; 2020 [cited 2024 Feb 10]. Available from:
198 https://www.gestation.net/GROW_documentation.pdf
- 199 34. RCOG [Internet]. [cited 2024 Feb 10]. Small-for-Gestational-Age Fetus, Investigation and
200 Management (Green-top Guideline No. 31). Available from:
201 [https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/small-for-](https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/small-for-gestational-age-fetus-investigation-and-management-green-top-guideline-no-31/)
202 [gestational-age-fetus-investigation-and-management-green-top-guideline-no-31/](https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/small-for-gestational-age-fetus-investigation-and-management-green-top-guideline-no-31/)
- 203 35. Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal
204 surveillance, diagnosis, and management. *Am J Obstet Gynecol*. 2011 Apr;*204*(4):288–300.
- 205 36. Gardosi J, Francis A, Turner S, Williams M. Customized growth charts: rationale, validation
206 and clinical benefits. *Am J Obstet Gynecol*. 2018 Feb 1;*218*(2):S609–18.
- 207 37. Clausson B, Gardosi J, Francis A, Cnattingius S. Perinatal outcome in SGA births defined
208 by customised versus population-based birthweight standards. *BJOG Int J Obstet Gynaecol*.
209 2001 Aug;*108*(8):830–4.
- 210 38. Ego A, Subtil D, Grange G, Thiebaugeorges O, Senat MV, Vayssiere C, et al. Customized
211 versus population-based birth weight standards for identifying growth restricted infants: a
212 French multicenter study. *Am J Obstet Gynecol*. 2006 Apr;*194*(4):1042–9.
- 213 39. McCowan LME, Harding JE, Stewart AW. Customized birthweight centiles predict SGA
214 pregnancies with perinatal morbidity. *BJOG Int J Obstet Gynaecol*. 2005 Aug;*112*(8):1026–
215 33.
- 216 40. Francis A, Hugh O, Gardosi J. Customized vs INTERGROWTH-21st standards for the

- 217 assessment of birthweight and stillbirth risk at term. *Am J Obstet Gynecol*. 2018 Feb
218 1;218(2):S692–9.
- 219 41. Gardosi J, Hugh O. Stillbirth risk and smallness for gestational age according to Hadlock,
220 INTERGROWTH-21st, WHO, and GROW fetal weight standards: analysis by maternal
221 ethnicity and body mass index. *Am J Obstet Gynecol*. 2023 Nov 1;229(5):547.e1-547.e13.
- 222 42. Kierans WJ, Joseph KS, Luo ZC, Platt R, Wilkins R, Kramer MS. Does one size fit all? The
223 case for ethnic-specific standards of fetal growth. *BMC Pregnancy Childbirth*. 2008 Jan
224 8;8:1.
- 225 43. Seaton SE, Yadav KD, Field DJ, Khunti K, Manktelow BN. Birthweight centile charts for
226 South Asian infants born in the UK. *Neonatology*. 2011;100(4):398–403.
- 227 44. Hanley GE, Janssen PA. Ethnicity-specific birthweight distributions improve identification of
228 term newborns at risk for short-term morbidity. *Am J Obstet Gynecol*. 2013
229 Nov;209(5):428.e1-6.
- 230 45. Dienes Z. *Understanding Psychology as a Science*. New York, USA: Palgrave Macmillan;
231 2008.
- 232 46. Royall R. *Statistical Evidence. A Likelihood Paradigm*. New York: Chapman & Hall; 1997.
- 233 47. Berry DA. Bayesian clinical trials. *Nat Rev Drug Discov*. 2006 Jan;5(1):27–36.
- 234 48. Bland JM, Altman DG. Bayesians and frequentists. *BMJ*. 1998 Oct 24;317(7166):1151–60.
- 235 49. Goligher EC, Tomlinson G, Hajage D, Wijesundera DN, Fan E, Jüni P, et al. Extracorporeal
236 Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior
237 Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical
238 Trial. *JAMA*. 2018 Dec 4;320(21):2251–9.
- 239 50. Quintana M, Viele K, Lewis RJ. Bayesian Analysis: Using Prior Information to Interpret the
240 Results of Clinical Trials. *JAMA*. 2017 Oct 24;318(16):1605–6.
- 241 51. Yarnell CJ, Abrams D, Baldwin MR, Brodie D, Fan E, Ferguson ND, et al. Clinical trials in
242 critical care: can a Bayesian approach enhance clinical and scientific decision making?
243 *Lancet Respir Med*. 2021 Feb;9(2):207–16.